4109763
doi
10.1016/j.addr.2020.10.007
oai:zenodo.org:4109763
user-eu
Đorđević, Snežana
Centro de Investigación Príncipe Felipe, Polymer Therapeutics Lab, Av. Eduardo Primo Yúfera 3, E-46012 Valencia, Spain
Conejos-Sánchez, Inmaculada
Centro de Investigación Príncipe Felipe, Polymer Therapeutics Lab, Av. Eduardo Primo Yúfera 3, E-46012 Valencia, Spain
Vicent, María J.
Centro de Investigación Príncipe Felipe, Polymer Therapeutics Lab, Av. Eduardo Primo Yúfera 3, E-46012 Valencia, Spain
Therapeutic potential of polypeptide-based conjugates: Rational design and analytical tools that can boost clinical translation
Melnyk, Tetiana
Centro de Investigación Príncipe Felipe, Polymer Therapeutics Lab, Av. Eduardo Primo Yúfera 3, E-46012 Valencia, Spain
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Polypeptide, Polymer therapeutics, Polypeptide-drug conjugates, Analytical tools, Controlled drug delivery, Bioresponsiveness, Physico-chemical characterization
<p>The clinical success of polypeptides as polymeric drugs, covered by the umbrella term “polymer therapeutics,” combined with related scientific and technological breakthroughs, explain their exponential growth in the development of polypeptide-drug conjugates as therapeutic agents. A deeper understanding of the biology at relevant pathological sites and the critical biological barriers faced, combined with advances regarding controlled polymerization techniques, material bioresponsiveness, analytical methods, and scale up-manufacture processes, have fostered the development of these nature-mimicking entities. Now, engineered polypeptides have the potential to combat current challenges in the advanced drug delivery field. In this review, we will discuss examples of polypeptide-drug conjugates as single or combination therapies in both preclinical and clinical studies as therapeutics and molecular imaging tools. Importantly, we will critically discuss relevant examples to highlight those parameters relevant to their rational design, such as linking chemistry, the analytical strategies employed, and their physicochemical and biological characterization, that will foster their rapid clinical translation.</p>
Zenodo
2020-10-20
info:eu-repo/semantics/article
4109762
user-eu
award_title=Towards the design of Personalised Polymer-based Combination Nanomedicines for Advanced Stage Breast Cancer Patients; award_number=648831; award_identifiers_scheme=url; award_identifiers_identifier=https://cordis.europa.eu/projects/648831; funder_id=00k4n6c32; funder_name=European Commission;
1603240016.349395
17777854
md5:2199a259203fe65eaeeb722eefb657aa
https://zenodo.org/records/4109763/files/1-s2.0-S0169409X20301447-main.pdf
public
Advanced Drug Delivery Reviews
2020-10-20